On September 10, 2018, Xbrane Biopharma announced that it has decided to shift its strategic focus of capital and resources toward biosimilars and away from its pipeline of generic long-acting injectables.  In addition to moving forward with its pivotal clinical trial for Xlucane, its proposed biosimilar of Lucentis® (ranibizumab), Xbrane states that it is accelerating development of Xcimzane and  Xoncane, biosimilar candidates referencing Cimzia® (certoizumab pegol) and Oncaspar® (pegaspargase), respectively, and will also initiate development of two additional biosimilars of biologics with patent expirations in 2026-2028.  According to Xbrane, “further development of generic long acting injectables beyond Spherotide (generic long acting triptorelin) will only be pursued if additional resources become available.”  Xbrane further states that it will initially fund the development of its biosimilar pipeline using resources freed up from Xlucane development, but notes that long-term successful development will require it to raise sufficient capital in the market.